[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.171.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 1985

Etretinate Therapy for PsoriasisReduction of Antibody-Dependent Cell-Mediated Cytotoxicity of Polymorphonuclear Leukocytes

Author Affiliations

From the Clinical Pharmacology Unit, Department of Dermatology (Drs Ellis, Grekin, and Voorhees and Mr Kang), and Department of Internal Medicine (Dr LoBuglio), University of Michigan Medical Center, and Dermatology Service, Veterans Administration Medical Center (Drs Ellis, Grekin, and Voorhees), Ann Arbor. Dr LoBuglio is now with the Comprehensive Cancer Care Center, University of Alabama, Birmingham.

Arch Dermatol. 1985;121(7):877-880. doi:10.1001/archderm.1985.01660070067017
Abstract

• We monitored the antibody-dependent cell-mediated cytotoxicity of polymorphonuclear leukocytes from 14 patients with psoriasis before and during etretinate therapy. Neutrophils obtained from the patients with psoriasis at pretherapy demonstrated significantly greater cytotoxic activity than control cells. After four weeks of etretinate therapy, the cytotoxicity of neutrophils from the psoriatic patients decreased significantly and was no longer significantly different from the control value (at a 1:1 effector-to-target ratio). The decline in neutrophil cytotoxicity preceded significant clearing of our patients' psoriasis. The reduction in the antibody-dependent cell-mediated cytotoxicity of polymorphonuclear leukocytes from patients with psoriasis occurs early during therapy and may represent one of the mechanisms of action of etretinate.

(Arch Dermatol 1985;121:877-880)

×